PDCD1 and neoplasm: Apart from TMB analysis, the interpretation of mutations in individual tumor-driver or suppressor genes as pathogenic or likely pathogenic is also rapidly gaining importance for predicting the clinical response to PD-1 blockade in NSCLC.